Contrasting 60 Degrees Pharmaceuticals (SXTP) and Its Peers

60 Degrees Pharmaceuticals (NASDAQ:SXTP) is one of 896 publicly-traded companies in the “Pharmaceuticals” industry, but how does it contrast to its competitors? We will compare 60 Degrees Pharmaceuticals to related companies based on the strength of its dividends, analyst recommendations, valuation, risk, profitability, earnings and institutional ownership.

Profitability

This table compares 60 Degrees Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
60 Degrees Pharmaceuticals	-650.21%	N/A	-136.81%
60 Degrees Pharmaceuticals Competitors	-2,380.38%	-217.94%	-15.54%

Volatility & Risk

60 Degrees Pharmaceuticals has a beta of 2.47, meaning that its share price is 147% more volatile than the S&P 500. Comparatively, 60 Degrees Pharmaceuticals’ competitors have a beta of -3.71, meaning that their average share price is 471% less volatile than the S&P 500.

Institutional and Insider Ownership

8.0% of 60 Degrees Pharmaceuticals shares are held by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are held by institutional investors. 1.7% of 60 Degrees Pharmaceuticals shares are held by company insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and target prices for 60 Degrees Pharmaceuticals and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
60 Degrees Pharmaceuticals	1	2	1	0	2.00
60 Degrees Pharmaceuticals Competitors	7798	13888	25778	1037	2.41

60 Degrees Pharmaceuticals presently has a consensus target price of $13.85, suggesting a potential upside of 2,228.12%. As a group, “Pharmaceuticals” companies have a potential upside of 25.60%. Given 60 Degrees Pharmaceuticals’ higher probable upside, equities research analysts plainly believe 60 Degrees Pharmaceuticals is more favorable than its competitors.

Earnings and Valuation

This table compares 60 Degrees Pharmaceuticals and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
60 Degrees Pharmaceuticals	$1.41 million	-$7.36 million	-0.12
60 Degrees Pharmaceuticals Competitors	$3.56 billion	$3.19 billion	555.10

60 Degrees Pharmaceuticals’ competitors have higher revenue and earnings than 60 Degrees Pharmaceuticals. 60 Degrees Pharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Summary

60 Degrees Pharmaceuticals competitors beat 60 Degrees Pharmaceuticals on 9 of the 13 factors compared.

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia.